Navigation Links
Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
Date:10/18/2010

CARLSBAD, Calif., Oct. 18 /PRNewswire/ -- Excaliard Pharmaceuticals, Inc. announced today the appointment of Thomas G. Wiggans as Chairman of its Board of Directors. Mr. Wiggans brings to the role more than 30 years of experience in successfully developing and commercializing drugs with several notable successes in the dermatology field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company focused on the clinical development and commercialization of novel drugs for the amelioration of skin scarring and other fibrotic disorders.

"We are delighted to have Mr. Wiggans join Excaliard," commented Gordon Foulkes, President of Excaliard, and Managing Director of RiverVest Venture Partners. "Tom has successfully led dermatology companies, such as Connetics and Peplin, and his guidance in Excaliard's growth will be invaluable."

"Excaliard has made impressive clinical progress in advancing its lead product EXC-001 through three Phase II clinical studies in skin scarring," commented Mr. Wiggans. "I am looking forward to working with the Excaliard team to bring EXC-001 and the company's product pipeline forward."

In August 2010, Excaliard announced positive results from its Phase 2 clinical trial of EXC 001. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo at 12 weeks post surgery. The final analysis for this study will be conducted 24 weeks after surgery. The data for this study and two additional skin scarring Phase 2 studies will be available later in 2010.

Most recently Mr. Wiggans was Chairman of the Board of Directors and Chief Executive Officer of Peplin, Inc., which was acquired in 2009 by LEO Pharma of Copenhagen, Denmark. Prior to that, he served as CEO of Connetics Corporation from 1994 until 2006, when the company was acquired by Stiefel Laboratories. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, a biotechnology company. From 1980 to 1992, Mr. Wiggans served in various positions at Ares-Serono Group, a pharmaceutical company, including President of its U.S. pharmaceutical operations. Mr. Wiggans currently serves as a Director of Onyx Pharmaceuticals, Sangamo Biosciences and Somaxon Pharmaceuticals. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

About EXC 001

EXC 001 is a new generation antisense medicine that may interrupt the process of fibrosis by inhibiting a growth factor. Unsatisfactory skin scarring can be associated with virtually every surgical procedure, including elective, reconstructive, or emergency surgery, traumatic wounds, and various dermatologic conditions, such as hypertrophic scars and keloids. Prevention and treatment of unsatisfactory skin scarring is an important unmet medical need.

About Excaliard Pharmaceuticals

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. EXC 001 was co-discovered by Isis Pharmaceuticals  Inc., (Nasdaq: ISIS) and Excaliard, and licensed to Excaliard Pharmaceuticals.


'/>"/>
SOURCE Excaliard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Excaliard Announces Positive Data From Phase 2 Clinical Trial of Its Anti-Scarring Drug, EXC 001
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):